| 000 | 01349nam a2200169Ia 4500 | ||
|---|---|---|---|
| 003 | OSt | ||
| 005 | 20260718102240.0 | ||
| 008 | 230508s2022 xx 000 0 und d | ||
| 050 |
_aAllied HD 9666.4 _bL36 2022 |
||
| 100 | 1 | _aLaMattina, John L. | |
| 245 | 1 | 0 |
_aPharma and profits : _bbalancing innovation, medicine, and drug prices / _cJohn L. LaMattina. |
| 264 |
_aHoboken, NJ : _bJohn Wiley & Sons, _c2022. |
||
| 300 |
_axii, 100 pages ; _c23 cm. |
||
| 500 | _aIncludes index. | ||
| 505 | 0 | _ach. 1. The $1000 pill: the fiscal consequences of curing hepatitis C — ch. 2. Enter the players: FDA approval does not guarantee commercial success — ch. 3. Pandemic: mRNA vaccine and the race for a cure — ch. 4. Federal investment in r&d: why the government does not deserve a piece of biopharma’s profits? — ch. 5. Inaulin: the true cost of a 100-year-old drug — ch. 6. The costly alzheimer’s disease drug: a questionable breakthrough — ch. 7. Gene therapy: how much a life worth? — ch. 8. Proving the value of expensive drug: should we pay for drugs whose ultimate value is unknown? — cn. 9. Generic drugs: built-in cost controls — ch. 10. About those soaring pharma profits: are they driving healthcare costs? — ch. 11. Schemes to lower drug prices: the impact of reduced resources on r&d. | |
| 942 |
_2lcc _cBK _kEAC Cavite-Allied |
||
| 999 |
_c33453 _d33453 |
||